These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28476823)

  • 41. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis.
    Gallos ID; Shehmar M; Thangaratinam S; Papapostolou TK; Coomarasamy A; Gupta JK
    Am J Obstet Gynecol; 2010 Dec; 203(6):547.e1-10. PubMed ID: 20934679
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of nuclear progesterone receptors (nPRs), membrane progesterone receptors (mPRs) and progesterone receptor membrane components (PGRMCs) in the human endometrium after 6 months levonorgestrel low dose intrauterine therapy.
    Sletten ET; Smaglyukova N; Ørbo A; Sager G
    J Steroid Biochem Mol Biol; 2020 Sep; 202():105701. PubMed ID: 32479983
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Levonorgestrel-releasing intrauterine system (LNG-IUS) as an effective treatment option for endometrial hyperplasia: a 15-year follow-up study.
    Scarselli G; Bargelli G; Taddei GL; Marchionni M; Peruzzi E; Pieralli A; Mattei A; Buccoliero AM; Fambrini M
    Fertil Steril; 2011 Jan; 95(1):420-2. PubMed ID: 20723889
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of endometrioid adenocarcinoma despite Levonorgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG/BSGE Guideline on the Management of Endometrial Hyperplasia.
    van der Meer AC; Hanna LS
    Clin Obes; 2017 Feb; 7(1):54-57. PubMed ID: 27984850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effects of levonorgestrel-releasing intrauterine system on endometrial estrogen and progesterone receptors in patients with endometrial hyperplasia].
    Weng M; Li L; Feng S; Xie M; Hong S
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Sep; 32(9):1350-4. PubMed ID: 22985581
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis.
    Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
    Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():104-110. PubMed ID: 30342311
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
    El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
    Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: A systematic review.
    Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
    Acta Obstet Gynecol Scand; 2019 Sep; 98(9):1086-1099. PubMed ID: 30793281
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.
    Kudesia R; Singer T; Caputo TA; Holcomb KM; Kligman I; Rosenwaks Z; Gupta D
    Am J Obstet Gynecol; 2014 Mar; 210(3):255.e1-4. PubMed ID: 24211482
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.
    Amezcua CA; Lu JJ; Felix JC; Stanczyk FZ; Zheng W
    Gynecol Oncol; 2000 Nov; 79(2):169-76. PubMed ID: 11063639
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study.
    Pashov AI; Tskhay VB; Ionouchene SV
    Gynecol Endocrinol; 2012 Jul; 28(7):559-61. PubMed ID: 22296608
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy.
    Gunderson CC; Dutta S; Fader AN; Maniar KP; Nasseri-Nik N; Bristow RE; Diaz-Montes TP; Palermo R; Kurman RJ
    Gynecol Oncol; 2014 Jan; 132(1):33-7. PubMed ID: 24316307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study.
    Barr CE; Sergeant JC; Agnew HJ; Bolton J; McVey RJ; Crosbie EJ
    BJOG; 2023 Jul; 130(8):941-948. PubMed ID: 36715558
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature.
    Baker J; Obermair A; Gebski V; Janda M
    Gynecol Oncol; 2012 Apr; 125(1):263-70. PubMed ID: 22196499
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review.
    Depypere H; Inki P
    Climacteric; 2015; 18(4):470-82. PubMed ID: 25553775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful pregnancy following insertion of a levonorgestrel-releasing intrauterine system in two infertile patients with complex atypical endometrial hyperplasia.
    Qi X; Zhao W; Duan Y; Li Y
    Gynecol Obstet Invest; 2008; 65(4):266-8. PubMed ID: 18196936
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study.
    Kim MK; Seong SJ; Park DC; Hong JH; Roh JW; Kang SB
    J Gynecol Oncol; 2020 Jul; 31(4):e51. PubMed ID: 32266800
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
    Wheeler DT; Bristow RE; Kurman RJ
    Am J Surg Pathol; 2007 Jul; 31(7):988-98. PubMed ID: 17592264
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Postoperative administration of dienogest plus estradiol valerate versus levonorgestrel-releasing intrauterine device for prevention of pain relapse and disease recurrence in endometriosis patients.
    Morelli M; Sacchinelli A; Venturella R; Mocciaro R; Zullo F
    J Obstet Gynaecol Res; 2013 May; 39(5):985-90. PubMed ID: 23551827
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
    Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.